Literature DB >> 15906405

Role of histone and transcription factor acetylation in diabetes pathogenesis.

Steven G Gray1, Pierre De Meyts.   

Abstract

Globally, diabetes (and, in particular, type 2 diabetes) represents a major challenge to world health. Currently in the United States, the costs of treating diabetes and its associated complications exceed 100 billion US dollars annually, and this figure is expected to soar in the near future. Despite decades of intense research efforts, the genetic basis of the events involved in the pathogenesis of diabetes is still poorly understood. Diabetes is a complex multigenic syndrome primarily due to beta-cell dysfunction associated with a variable degree of insulin resistance. Recent advances have led to exciting new developments with regard to our understanding of the mechanisms that regulate insulin transcription. These include data that implicate chromatin as a critical regulator of this event. The 'Histone Code' is a widely accepted hypothesis, whereby sequential modifications to the histones in chromatin lead to regulated transcription of genes. One of the modifications used in the histone code is acetylation. This is probably the best characterized modification of histones, which is carried out under the control of histone acetyltransferases (HATs) and histone deacetylases (HDACs). These enzymes also regulate the activity of a number of transcription factors through acetylation. Increasing evidence links possible dysregulation of these mechanisms in the pathogenesis of diabetes, with important therapeutic implications. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906405     DOI: 10.1002/dmrr.559

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  41 in total

Review 1.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 2.  Vascular Smooth Muscle as a Target for Novel Therapeutics.

Authors:  Karen E Porter; Kirsten Riches
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

3.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Kathryn T Iacono; Kathryn Bembas; Ran Tao; Samik Basu; James L Riley; Wayne W Hancock; Yuan Shen; Sandra J Saouaf; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

Review 4.  Epigenetic phenomena linked to diabetic complications.

Authors:  Luciano Pirola; Aneta Balcerczyk; Jun Okabe; Assam El-Osta
Journal:  Nat Rev Endocrinol       Date:  2010-11-02       Impact factor: 43.330

Review 5.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

6.  Use of polyamine derivatives as selective histone deacetylase inhibitors.

Authors:  Patrick M Woster
Journal:  Methods Mol Biol       Date:  2011

Review 7.  Epigenetic mechanisms in diabetic vascular complications.

Authors:  Marpadga A Reddy; Rama Natarajan
Journal:  Cardiovasc Res       Date:  2011-01-25       Impact factor: 10.787

8.  Epigenetics of diabetic complications.

Authors:  Louisa M Villeneuve; Rama Natarajan
Journal:  Expert Rev Endocrinol Metab       Date:  2010-01

9.  Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways.

Authors:  Jane Palsgaard; Charlotte Brøns; Martin Friedrichsen; Helena Dominguez; Maja Jensen; Heidi Storgaard; Camilla Spohr; Christian Torp-Pedersen; Rehannah Borup; Pierre De Meyts; Allan Vaag
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

Review 10.  FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity.

Authors:  Zhaocai Zhou; Xiaomin Song; Bin Li; Mark I Greene
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.